Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents.
PURPOSE
To assess the psychometric properties of the Greek Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) and evaluate the factors that influence treatment satisfaction of patients with neovascular age-related macular degeneration (nAMD).


METHODS
The MacTSQ was translated into Greek and administered to 176 patients. All patients completed the SF-12 Health Survey and the Macular disease Dependent Quality of Life Questionnaire (MacDQoL) and underwent vision measurements. For test-retest reliability, a subset of 19 participants completed the MacTSQ twice, two weeks apart. Stepwise multiple linear regression analyses were performed to identify predictors of treatment satisfaction. Change in MacTSQ scores over time was assessed on 83 patients who completed the MacTSQ at a follow-up visit, one year later.


RESULTS
The intraclass correlation coefficients between the first and second test-retest administration ranged from 0.88 to 0.98 for the items and total score. Internal reliability of the total score was adequate (Cronbach's a = 0.837). Principal component analysis revealed three subscales (effectiveness, information provision and convenience, impact). The MacTSQ score showed significant correlations with SF-12 summary scales and MacDQoL scores (ρ = 0.16-0.27). The most important factor that determined the satisfaction was mental health. Distance visual acuity (VA) in better eye was the best predictor of the effectiveness subscale, and the total number of injections was a negative predictor for the convenience subscale. Treatment satisfaction increased at one-year follow-up, despite the deterioration in distance VA.


CONCLUSIONS
The Greek MacTSQ is a reliable and valid instrument for assessing nAMD patients' perceptions of treatment satisfaction, especially using its three new subscales. Treatment satisfaction is multifactorial and was primarily determined by patients' mental health status.
['Marakis|Theodoros P|TP|', 'Koutsandrea|Chrysanthi|C|', 'Chatzistefanou|Klio I|KI|', 'Tountas|Yannis|Y|']
D000368:Aged D000369:Aged, 80 and over D020533:Angiogenesis Inhibitors D020256:Choroidal Neovascularization D005260:Female D006801:Humans D008268:Macular Degeneration D008297:Male D008875:Middle Aged D017060:Patient Satisfaction D011594:Psychometrics D011788:Quality of Life D000069579:Ranibizumab D012044:Regression Analysis D011795:Surveys and Questionnaires D042461:Vascular Endothelial Growth Factor A D014792:Visual Acuity
Age-related macular degeneration Psychometric properties Treatment satisfaction questionnaire Predictors Greece